Información del producto
SB273005 is a monoclonal antibody that binds to all-trans retinoic acid (ATRA) and prevents it from binding to ATRA receptors. This binding inhibits the production of growth factor-β1, collagen, and ATP in tumor cells. SB273005 has been shown to be effective in treating patients with glioma, as it decreases the size of tumors and prolongs survival time. The efficacy of SB273005 has also been demonstrated in tissue culture experiments on mouse glioma cells. The monoclonal antibody is administered intravenously by infusion over a period of 30 minutes each week for 3 weeks.
Propiedades químicas
Consulta técnica sobre: 3D-FIA67831 SB273005
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
